Rapport Therapeutics (RAPP) Other Non-Current Assets (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Other Non-Current Assets of $1.1 million for Q1 2026, up 400.95% year-over-year from $211000.0 in Q1 2025, and up 7.31% quarter-over-quarter from $985000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Other Non-Current Assets for 4 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 400.95% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 400.95% YoY), while the FY2025 annual figure was $985000.0, up 515.62% from the prior year.
- Other Non-Current Assets rose to $1.1 million in Q1 2026 per RAPP's latest filing, from $985000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.1 million in Q3 2025 and bottomed at $160000.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $604888.9 across 4 years, with a median of $551000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets plunged 70.96% — and 2025, when it jumped 515.62%.
- Rapport Therapeutics' Other Non-Current Assets stood at $551000.0 in 2023, then slumped by 70.96% to $160000.0 in 2024, then surged by 515.62% to $985000.0 in 2025, then advanced by 7.31% to $1.1 million in 2026.
- Business Quant data shows RAPP's Other Non-Current Assets at $1.1 million in Q1 2026, $985000.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 985,000.00 |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 160,000.00 |
| Sep 30, 2024 | 189,000.00 |
| Jun 30, 2024 | 189,000.00 |
| Dec 31, 2023 | 551,000.00 |